Key facts
- Retension Pharmaceutical’s last known valuation is $50.0M (May 2025).
- It has raised $22.4M; the latest was Early Stage VC ($12.3M) in May 2025.
- Notable investors include Dais Partners, Collage Venture Partners, Green Park & Golf Ventures, Transhuman Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Retension Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Retension Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Retension Pharmaceutical
Developer of therapeutic drugs designed for patients with hypertension. The company's drug is a unique second-generation inhibitor that preferentially targets cardiovascular tissues, enabling patients to control blood pressure and improve cardiovascular health.
- Sector
- Healthcare
- HQ
- Falls Church, VA, United States
- Founded
- 2023
- Employees
- 9
- Website
- retensionpharma.com/
- Ownership
- Privately Held (backing)
Retension Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Retension Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Retension Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.